Pentavalent meningococcal conjugate vaccine - PATH/ Serum Institute of India

Drug Profile

Pentavalent meningococcal conjugate vaccine - PATH/ Serum Institute of India

Alternative Names: MenACYWX; Meningococcal vaccine groups A,C,W-135, Y, X conjugate - PATH; Meningococcal-ACYWX-conjugate-vaccine; NmCV-5; Pentavalent-meningococcal-conjugate-vaccine-A-C-Y-W-135-X; Polyvalent meningitis vaccine - PATH; Thermostable pentavalent conjugate meningococcal vaccine - PATH

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PATH; Serum Institute of India
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Meningococcal infections

Most Recent Events

  • 15 Nov 2017 Phase-II clinical trials in Meningococcal infections (In volunteers, In infants, Prevention) in Mali (IM) (NCT03295318)
  • 03 Oct 2017 Serum Institute of India plans a phase II trial for Meningococcal infections (In infants, In volunteers) in Mali (IM) (NCT03295318)
  • 18 Oct 2016 Early research in Meningococcal infections (Prevention) in India before October 2016 (Serum Institute of India pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top